Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Randomized trials have shown a survival benefit to using drug-eluting stents (DES) rather than bare-metal stents (BMS) in heart disease patients. Now, the…
NEW YORK (Reuters Health) – In the treatment of lower urinary tract symptoms in men, extended-release oxybutynin plus tamsulosin is more effective than tamsulosin alone and just as…
NEW YORK (Reuters Health) – Adults with subclinical hypothyroidism are at increased risk for heart failure and for changes in cardiac function, new research suggests. Subclinical hyperthyroidism, by…
NEW YORK (Reuters Health) – The risk of lung cancer is increased in patients with rheumatoid arthritis, even after taking into account the effects of tobacco and asbestos…
NEW YORK (Reuters Health) – The results of a randomized trial suggest that statins may be a useful treatment for Raynaud’s phenomenon and digital ulcers that can accompany…
NEW YORK (Reuters Health) – The results of a new study indicate that the intradermal vaccination route offers greater protection against influenza than the standard intramuscular route in…
NEW YORK (Reuters Health) – Patients who quit smoking after undergoing coronary artery bypass graft (CABG) surgery can expect to live 3 years longer than patients who continue…
NEW YORK (Reuters Health) – In patients with recently diagnosed chronic obstructive pulmonary disease (COPD), the use of ipratropium may increase all-cause and cardiovascular mortality, US researchers report.…
NEW YORK (Reuters Health) – In children with allergic rhinitis, sublingual immunotherapy (SLIT) can help prevent mild persistent asthma, new skin sensitizations and can reduce bronchial hyperactivity, Italian…
NEW YORK (Reuters Health) – Beta-adrenergic receptor antagonists are no more effective than other medications used for primary prevention of heart failure in patients with hypertension, according to…
